Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.
Actively Recruiting
Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults with chronic heart failure who have a reduced left ventricular ejection fraction below 40%. Participants must have been diagnosed with chronic heart failure for at least three months and be in New York Heart Association classes II to IV. The study is a phase III, randomized, double-blind trial aimed at assessing whether this combination improves outcomes compared to placebo plus empagliflozin. Participants are randomly assigned to one of two groups with equal chance one group receives vicadrostat with empagliflozin tablets, and the other receives placebo with empagliflozin tablets. The study medicines are taken once daily for about six months up to three and a half years. Participants continue their regular heart failure treatments alongside the study drugs. The study monitors participants throughout this period, which can last up to 43 months. During the study, participants attend regular visits to the study site and may receive some follow-up calls. They answer questionnaires about their symptoms and overall well-being. Doctors record any worsening heart failure symptoms, hospitalizations due to heart failure, or deaths to compare the two groups. Health status and any side effects are regularly checked. The primary outcome is the time to first cardiovascular death, hospitalization for heart failure, or urgent heart failure visit.
Actively Recruiting
Researchers are evaluating the combination of vicadrostat BI 690517 and empagliflozin for adults aged 18 and older who have heart failure symptoms and a left ventricular ejection fraction LVEF of 40% or more. The study aims to find out whether taking vicadrostat with empagliflozin helps people with heart failure. This is a phase III randomized, double-blind, parallel-group trial sponsored by Boehringer Ingelheim. Participants are randomly assigned to one of two groups one group takes vicadrostat combined with empagliflozin tablets once daily, and the other group takes a placebo combined with empagliflozin tablets once daily. The study has no fixed duration participants can stay in the study as long as they benefit from treatment and can tolerate it. During the study, participants visit their doctors regularly for health checks and monitoring. Throughout the study, participants undergo regular health assessments including monitoring for any unwanted effects. Study staff may also contact participants by phone and ask them to answer questions about their well-being. The main outcome being measured is the time to the first event of cardiovascular death, hospitalization for heart failure, or urgent heart failure visit over up to 42 months. Other outcomes include symptom scores, blood pressure changes, and kidney function. The study runs until enough data is collected to evaluate the treatments effects.
Actively Recruiting
Researchers are evaluating the impact of individualized sodium management during hemodialysis compared to standard treatment for patients with end stage renal disease on dialysis. The study aims to assess differences in fluid control, weight gain between dialysis sessions, blood pressure stability during treatment, and the rate of adverse events occurring during dialysis. Quality of life and overall wellbeing of patients will also be monitored to understand the effects of sodium control in this setting. Participants will be randomly assigned to one of two groups one receiving hemodialysis or hemodiafiltration with a sodium zero-diffusive treatment setting enabled on the dialysis machine, and the other receiving standard dialysis treatment without sodium control. Each patient will undergo thrice weekly dialysis sessions over a 12-week period, totaling 36 treatments. This approach allows comparison of the sodium management option available on 6008 HD dialysis machines versus the same machines operating without this feature. During the study, researchers will collect clinical data including measurements of fluid status, interdialytic weight gain, hemodynamic stability, and dialysis-related adverse events after 12 weeks of treatment. Patient-reported outcomes such as thirst, fatigue, hypotensive episodes, health-related quality of life, and general health status will also be assessed. Monitoring will ensure safety and collect detailed information about treatment effects over the 12-week trial period.
Actively Recruiting
Researchers are studying the effects of a 21-day comprehensive spa care program on adults aged 40 to 70 years with chronic kidney and urinary tract conditions, including recurrent inflammation, nephrolithiasis, post-surgical recovery, and chronic prostatitis. The study aims to objectively measure changes in clinical and laboratory outcomes before and after treatment at a spa facility in Marinsk Lzn, Czech Republic. The treatment includes natural mineral spring water drinking three times daily, mineral water baths, mud therapy, carbon dioxide therapy, climate therapy, exercise therapy, and dietotherapy with nutritional counseling. Each participant receives 63 therapeutic procedures over 21 days, with some additional treatments prescribed individually by a spa physician. Assessments are done at the start and end of the treatment period. Participants undergo physical exams, ultrasound scans, blood and urine tests, body composition measurements, and psychometric questionnaire surveys at both time points. Data are pseudonymized and securely managed for analysis. The primary outcomes include changes in kidney function markers and urine cultures, while secondary outcomes assess quality of life, urinary symptoms, ultrasound findings, body composition, and vital signs. The total participation lasts for the 21-day spa treatment period.
Actively Recruiting
Researchers are evaluating whether the drug zilebesiran can reduce major cardiovascular events such as cardiovascular death, nonfatal heart attacks, strokes, or heart failure in adults with hypertension that is not well controlled and who have either established cardiovascular disease or are at high risk for it. This is a phase 3, randomized, double-blind, placebo-controlled study that will continue until a targeted number of cardiovascular events have occurred. Participants will receive either 300 mg of zilebesiran or a placebo by subcutaneous injection every six months, in addition to their standard antihypertensive medications, which must include a thiazide, thiazide-like, or loop diuretic. The study involves two parallel groups one receiving the active drug and the other receiving placebo, both as add-on therapies to current treatment. During the trial, participants will be regularly monitored for cardiovascular outcomes over approximately five years. The main measurement is the time to the first occurrence of a composite endpoint including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or heart failure events requiring hospitalization or urgent visits. Blood pressure changes at six months and other cardiovascular outcomes will also be assessed. Safety and effectiveness will be closely observed throughout the study period.